Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Corixa misses Melacine end point

CRXA's Melacine therapeutic vaccine for melanoma missed its primary end point in a Phase III trial. In the study,

Read the full 195 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE